Moderna Inc. said on Monday it generated about $18.4 billion in COVID-19 vaccine sales in 2022, meeting its forecast of $18 billion-$19 billion for the year.
The company also forecast minimum COVID-19 vaccine sales of about $5 billion in 2023, compared with its previous forecast of $4.5 billion to $5.5 billion in November.
The COVID vaccine maker continues to expect additional contracts for 2023, it said.
© 2026 Thomson/Reuters. All rights reserved.